Tawee Tanvetyanon

Tawee Tanvetyanon practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Tawee Tanvetyanon's NPI, 1750303905, was assigned on July 24, 2006. Tawee Tanvetyanon graduated from Chulalongkorn University Faculty of Medicine in 1996. Tawee Tanvetyanon holds Florida license ME93604.

Tawee Tanvetyanon's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Tawee Tanvetyanon's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Tawee Tanvetyanon to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Tawee Tanvetyanon practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Tawee Tanvetyanon's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Tawee Tanvetyanon is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Tawee Tanvetyanon's licenses on file in 3 states: Florida, Illinois and Pennsylvania.

Dmand AI lists lung cancer and lymphoma among the conditions Tawee Tanvetyanon treats.

CMS data shows 631 Medicare services from Tawee Tanvetyanon across 4 procedure codes in 2024, for 218 Medicare patients. Medicare paid $62,156 for them.

CMS counts 218 Medicare patients who saw Tawee Tanvetyanon in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Tawee Tanvetyanon's median patient age at 71, with 52% women.

In 2024, Tawee Tanvetyanon wrote 912 Medicare Part D claims for 168 patients. 80% of them were for generic drugs. CMS names the drug for 654 of them, across 29 drugs with 11 or more claims each, at $1,228,254 in total drug cost. In 2023, CMS named 570 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Tawee Tanvetyanon for performance year 2024, reported as part of a group. Tawee Tanvetyanon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Tawee Tanvetyanon as offering telehealth.

Dmand AI links 114 papers to Tawee Tanvetyanon, published from 2003 to 2025. 2023 was the busiest year, with 10. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Tawee Tanvetyanon has published most often in Clin Lung Cancer. Tawee Tanvetyanon's most frequent co-authors are Alberto A. Chiappori, MD, Benjamin C. Creelan, MD, MS and Jhanelle E. Gray, MD.

CMS Open Payments shows 3 general payments to Tawee Tanvetyanon from 3 drug and device companies from 2016 to 2021. Education make up the largest share, 56% of the total. Eli Lilly and Company paid the most, $113. It also lists 5 research payments totaling $2,225 from 2016 to 2020.

Tawee Tanvetyanon graduated from Chulalongkorn University Faculty of Medicine in 1996.

Tawee Tanvetyanon is in network with 8 carriers, including Excellus BlueCross BlueShield, Aetna and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.